Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Anti-obesity effects of Wumeishanzhayin: an integrated lipidomics and transcriptomics study

Huang X., Liao C., Peng B., Wang J., Zhang Y., He Q.

Animal Study on Type 2 Diabetes, published in Front Pharmacol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Front Pharmacol (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41194880
PMCID
PMC12584145
DOI
10.3389/fphar.2025.1697683

Abstract (original English)

Background The global prevalence of adult obesity has increased significantly, affecting over 890 million adults worldwide. Wumeishanzhayin (WMSZY), a formulation derived from four medicinal and edible botanical drugs, has shown efficacy in alleviating obesity and lipid metabolism disorders induced by high-fat and high-fructose (HFHF) diets. However, its underlying therapeutic mechanisms remain unclear. Objective This study aims to investigate the therapeutic effects and mechanisms of WMSZY in ameliorating obesity induced by a HFHF diet. Methods UPLC-MS/MS was used to characterize the metabolites of WMSZY. The effects of WMSZY on body weight gain, lipid metabolism, and glucose dysfunction were evaluated in a HFHF diet-induced murine model. Targeted lipidomics and transcriptomics analyses were performed to identify differentially altered lipids (DALs) and differentially expressed genes (DEGs). Computational approaches, including molecular docking simulation and dynamics simulations, were used to predict bioactive compound-target interactions. Key findings were validated through RT-qPCR and Western blot. Integrated transcriptomic and lipidomic analyses identified potential therapeutic targets. Results Sixteen metabolites were identified in WMSZY. Animal studies showed that WMSZY reduced body weight gain, improved lipid and glucose metabolism, and alleviated inflammation in HFHF d

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research